# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-263550
Filing Date
2025-11-04
Accepted
2025-11-04 07:15:52
Documents
76
Period of Report
2025-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | kymr-20250930.htm iXBRL | 10-Q | 3268813
2 | EX-31.1 | kymr-ex31_1.htm | EX-31.1 | 18228
3 | EX-31.2 | kymr-ex31_2.htm | EX-31.2 | 18100
4 | EX-32.1 | kymr-ex32_1.htm | EX-32.1 | 10507
5 | EX-32.2 | kymr-ex32_2.htm | EX-32.2 | 10382
| Complete submission text file | 0001193125-25-263550.txt |  | 12281227

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | kymr-20250930.xsd | EX-101.SCH | 1551020
79 | EXTRACTED XBRL INSTANCE DOCUMENT | kymr-20250930_htm.xml | XML | 2433600

Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39460 | Film No.: 251446441
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)